PV3B.F EYEPOINT PHARMAC. DL-01
- Market cap
- EUR 26.4M
- P/E
- -
- P/B
- 0.20x
- ROE
- -215.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PV3B.F undervalued?
Graham numberThe Graham number of EYEPOINT PHARMAC. DL-01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EYEPOINT PHARMAC. DL-01 fundamental analysis
No fundamental analysis for EYEPOINT PHARMAC. DL-01 yet.
EYEPOINT PHARMAC. DL-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EYEPOINT PHARMAC. DL-01
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase…
Full company profileEYEPOINT PHARMAC. DL-01 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EYEPOINT PHARMAC. DL-01 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 36.9M | 41.4M | 46.0M | 43.3M | 31.4M | 2.41M |
| Gross Profit | 28.8M | 33.1M | 41.4M | 39.6M | 29.3M | 1.35M |
| Operating Income | -55.3M | -78.9M | -75.1M | -146M | -243M | -369M |
| EBITDA | - | -96.6M | -69.0M | -129M | -229M | -367M |
| Net Income | -58.4M | -102M | -70.8M | -131M | -232M | -359M |
| EPS | -1.72 | -3.00 | -1.44 | -1.92 | -2.80 | -4.22 |
| Balance Sheet | ||||||
| Total Assets | 263M | 180M | 355M | 418M | 364M | 228M |
| Total Liabilities | 79.0M | 84.0M | 88.9M | 82.0M | 57.9M | 61.8M |
| Shareholders' Equity | 184M | 96.4M | 266M | 337M | 306M | 166M |
| Cash & Short-term Investments | 179M | 95.6M | 281M | 99.7M | 102M | 110M |
| Cash Flow | ||||||
| Operating Cash Flow | -50.1M | -65.0M | 1.88M | -126M | -240M | -286M |
| Capital Expenditure | 156K | 2.15M | 3.48M | 4.05M | 3.28M | 4.39M |
| Free Cash Flow | -50.3M | -67.2M | -1.61M | -130M | -243M | -290M |
| Ratios | ||||||
| ROE | -31.7% | -106.1% | -26.6% | -38.9% | -75.8% | -215.5% |
| ROA | -22.2% | -56.7% | -19.9% | -31.3% | -63.7% | -157.2% |
| Net Profit Margin | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% | -14,904.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
EYEPOINT PHARMAC. DL-01 dividends
EYEPOINT PHARMAC. DL-01 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Dec 9, 2020.
Who owns EYEPOINT PHARMAC. DL-01
- Insiders 3.53%
- Institutions 96.48%
- Public & others 0.00%
- Shares outstanding 86.2M
- Free float 60.7M
EYEPOINT PHARMAC. DL-01 company profile
- Company name
- EYEPOINT PHARMAC. DL-01
- Ticker
- PV3B.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 214
- Fiscal year end
- December
- Address
- 480 Pleasant Street, Watertown, MA, United States, 02472
- Phone
- 617 926 5000
- Website
- eyepoint.bio
About EYEPOINT PHARMAC. DL-01
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
EYEPOINT PHARMAC. DL-01 management
10- Dr. Jay S. Duker M.D.President, CEO & Director · born 1959
- Mr. George O. Elston CPAExecutive VP & CFO · born 1965
- Dr. Ramiro Ribeiro M.D., Ph.D.Chief Medical Officer · born 1983
- Dr. Marcia Sellos-Moura Ph.D.Chief Scientific Officer
- Mr. Ron I. Honig Esq.Chief Legal Officer & Company Secretary
- Ms. Jennifer LeonardChief People Officer & Senior VP of IT
- Mr. David Scott Jones M.A.Senior Vice President · born 1968
- Ms. Isabelle LefebvreChief Regulatory Officer
- Mr. Michael J. MaciocioChief Manufacturing Officer
- Mr. Michael CampbellChief Commercial Officer